

Clinical trials of sitagliptin

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
sitagliptin vs			
Stafford , 2011 [NCT00451113] n=NA follow-up:	-	older adults with type 2 diabetes mellitus	
sitagliptin vs control (add on MET)			
Reasner , 2011 [NCT00482729]) n=NA follow-up:	sitagliptin/metformin 50/500 mg bid uptitrated over 4 weeks to achieve maximum doses of sitagliptin/metformin 50/1000 mg bid versus metformin monotherapy	drug-naive patients with type 2 diabetes	Cross over NA
sitagliptin vs glimepiride (add on MET)			
Arechavaleta , 2011 [NCT00701090] n=516/519 follow-up: 30 weeks	sitagliptin 100 mg daily versus glimepiride (starting dose 1 mg/day and up-titrated, based upon patient's self-monitoring of blood glucose results, to a maximum dose of up to 6 mg/day)	patients with type 2 diabetes inadequately controlled on metformin monotherapy	Parallel groups double-blind
sitagliptin monotherapy vs metformin			
Aschner , 2010 [NCT00449930] n=528/522 follow-up: 24 weeks	once-daily sitagliptin 100 mg versus twice-daily metformin 1000 mg	treatment-naive patients with type 2 diabetes	double-blind
sitagliptin+pio vs metformin+pio			
Derosa , 2010 n=NA follow-up:	pioglitazone 30 mg plus sitagliptin 100 mg once a day versus pioglitazone 15 mg plus metformin 850 mg twice a day	poorly controlled type 2 diabetes mellitus patients	
sitagliptin vs placebo			

continued...

Trial	Treatments	Patients	Trials design and methods
Goldstein , 2007 [NCT00103857] n=NA follow-up:	sitagliptin 100 mg daily versus placebo	-	
Hanefeld , 2007 n=NA follow-up:	sitagliptin 25 mg or 50 mg or 100 mg daily versus placebo	-	
TECOS , 2015 [NCT00790205] n=7332/7339 follow-up: 3.0 years (median)	sitagliptin phosphate, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily versus placebo	patients with Type 2 Diabetes Mellitus having a history of cardiovascular disease and a hemoglobin A1c (HbA1c) of 6.5% to 8.0%	Parallel groups double-blind 38 countries
sitagliptin 50mg bid monotherapy vs placebo			
Scott* (sit vs pbo) , 2007 n=NA follow-up:	sitagliptin 50 mg b.i.d versus placebo	-	
sitagliptin monotherapy vs placebo			
Aschner , 2006 [NCT00087516] n=NA follow-up: 24 weeks	sitagliptin 100 or 200 mg daily versus placebo	patients with type 2 diabetes	
Barzilai , 2011 [NCT00305604] n=NA follow-up: 24 weeks	once-daily sitagliptin (100 or 50 mg, depending on renal function) versus placebo	elderly patients with type 2 diabetes	double-blind US
Chan , 2008 n=65/26 follow-up: 12 weeks	sitagliptin versus placebo	patients with type 2 diabetes and chronic renal insufficiency	double-blind
Mohan , 2009 n=NA follow-up: 18 weeks	sitagliptin 100mg once daily monotherapy versus placebo	Chinese, Indian, and Korean patients with type 2 diabetes inadequately controlled by diet and exercise.	double-blind
Nonaka , 2008 [NCT00371007] n=NA follow-up:	sitagliptin 100 mg daily monotherapy versus placebo	Japanese patients with type 2 diabetes	double-blind
Raz , 2006 n=NA follow-up:	sitagliptin 100 mg (or 200 mg) daily versus placebo	patients with type 2 diabetes mellitus and inadequate glycaemic control	

continued...

Trial	Treatments	Patients	Trials design and methods
sitagliptin vs placebo (add on insulin+/-MET)			
Vilsbll , 2010 [NCT00395343] n=322/319 follow-up:	once-daily sitagliptin 100 mg versus placebo	patients with type 2 diabetes inadequately controlled on long-acting, intermediate-acting or premixed insulin	double-blind
sitagliptin vs placebo (add on MET)			
Charbonnel , 2006 [NCT0086515] n=NA follow-up:	sitagliptin 100 mg daily (add-on to metformin therapy) versus placebo (add-on to metformin therapy);	-	
Nauck , 2007 [NCT00094770] n=NA follow-up:	sitagliptin 100 mg daily (add-on to metformin therapy) versus placebo (add-on to metformin therapy);	-	
raz , 2008 [NCT00337610] n=NA follow-up:	sitagliptin 100 mg once daily versus placebo	patients with type 2 diabetes	
Scott** (sit vs pbo on top met) , 2007 n=NA follow-up:	sitagliptin 100 mg daily (add-on to metformin therapy) versus placebo (add-on to metformin therapy).	patients with type 2 diabetes who were inadequately on MET monotherapy	
sitagliptin vs placebo (add on PIO)			
Rosenstock , 2006 [NCT00086502] n=NA follow-up: 24 weeks	sitagliptin 100 mg once daily versus placebo	patients with type 2 diabetes and inadequate glycemic control	double-blind
sitagliptin vs placebo (on top PIO)			
Rosenstock (sit on top pio vs pbo) , 2006 [NCT00086502] n=NA follow-up:	sitagliptin 100 mg daily (add-on to pioglitazone therapy) versus placebo (add-on to pioglitazone therapy);	-	
sitagliptin vs placebo (on-top glimepiride+/- metformine)			

continued...

Trial	Treatments	Patients	Trials design and methods
Hermansen , 2007 n=NA follow-up:	sitagliptin 100 mg daily (add-on to ongoing stable doses of glimepiride, alone or in combination with metformin)ocumen versus placebo (add-on to ongoing stable doses of glimepiride, alone or in combination with metformin);	-	
sitagliptin vs rosiglitazone (add on MET)			
Rigby , 2010 n=NA follow-up: 16 weeks	sitagliptin phosphate, 100 mg daily versus rosiglitazone maleate, 4 mg daily	type 2 diabetes mellitus inadequately controlled by metformin monotherapy	open
sitagliptin vs Sulphonylurea (on top MET)			
Al Sifri , 2011 n=507/514 follow-up:	sitagliptin 100 mg qd versus prestudy sulphonylurea	Muslim patients with type 2 diabetes who were treated with a stable dose of a sulphonylurea with or without metformin for at least 3 months	Parallel groups open
sitagliptin monotherapy vs voglibose			
Iwamoto , 2010 n=NA follow-up: 12 weeks	sitagliptin 50 mg once daily monotherapy versus voglibose 0.2 mg thrice daily before meals	Japanese patients with type 2 diabetes	double-blind
sitagliptin 50mg bid monotherapy vs glipizide			
Scott* (sit vs glipi) , 2007 n=NA follow-up: 12 weeks	sitagliptin 50mg bid versus glipizide 5mg to 20 mg dailyitm	patients with type 2 diabetes who have inadequate glycaemic control on diet and exercise	double-blind
sitagliptin vs metformin			
Goldstein (sit vs met) , 2007 n=NA follow-up:	sitagliptin 100 dailyily versus metformin 1000 mg or 2000 mg daily;imag	-	
Goldstein (sit+met vs met) , 2007 n=NA follow-up:	sitagliptin 50 mg daily plus metformin 1000 or 2000 mg daily4 <i>versus</i> <i>metformin1000or2000mgdaily</i>	-	
sitagliptin vs pioglitazone			
Prez-Monteverde , 2011 [NCT00541450] n=NA follow-up: 12 weeks	sitagliptin100 mg qd versus pioglitazone 15 mg qd, up-titrated to 30 mg after 6 weeks	drug-naive patients with type 2 diabetes	double-blind

More details and results :

- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on metformin at <http://www.trialresultscenter.org/go-Q509>
- antidiabetic drugs for diabetes type 2 in patients with insufficient glycaemic control with bitherapy at <http://www.trialresultscenter.org/go-Q511>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>
- insulin secretagogues - DPP-4 inhibitors for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q550>
- glucose lowering for cardiovascular prevention for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q576>

References

Stafford , 2011:

Stafford S, Elahi D, Meneilly GS Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus. J Am Geriatr Soc 2011;59:1148-9 [21668924] [10.1111/j.1532-5415.2011.03438.x](https://doi.org/10.1111/j.1532-5415.2011.03438.x)

Reasner, 2011:

Reasner C, Olansky L, Seck TL, Williams-Herman DE, Chen M, Terranella L, Johnson-Levonas AO, Kaufman KD, Goldstein BJ The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13:644-52 [21410627] [10.1111/j.1463-1326.2011.01390.x](https://doi.org/10.1111/j.1463-1326.2011.01390.x)

Archavaleta, 2011:

Archavaleta R, Seck T, Chen Y, Krobot KJ, O'Neill EA, Duran L, Kaufman KD, Williams-Herman D, Goldstein BJ Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011;13:160-8 [21199268] [10.1111/j.1463-1326.2010.01334.x](https://doi.org/10.1111/j.1463-1326.2010.01334.x)

Aschner, 2010:

Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD, Goldstein BJ Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:252-61 [20070351] [10.1111/j.1463-1326.2009.01187.x](https://doi.org/10.1111/j.1463-1326.2009.01187.x)

Derosa , 2010:

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010;59:887-95 [20015525] [10.1016/j.metabol.2009.10.007](https://doi.org/10.1016/j.metabol.2009.10.007)

Goldstein, 2007:

Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. *Diabetes Care* 2007;30:1979-87 [17485570] 10.2337/dc07-0627

Hanefeld, 2007:

Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. *Curr Med Res Opin* 2007;23:1329-39 [17559733] 10.1185/030079907X188152

TECOS, 2015:

Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR, Califf RM, Holman RR Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. *Am Heart J* 2013;166:983-989.e7 [24268212]

Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, Holman RR Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). *Diabetes Obes Metab* 2015;17:395-402 [25600421]

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med* 2015 Jul 16;373:232-42 [26052984] 10.1056/NEJMoa1501352

Scott* (sit vs pbo), 2007:

Scott R, Wu M, Sanchez M, Stein P Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. *Int J Clin Pract* 2007;61:171-80 [17156104] 10.1111/j.1742-1241.2006.01246.x

Aschner, 2006:

Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. *Diabetes Care* 2006;29:2632-7 [17130196] 10.2337/dc06-0703

Barzilai, 2011:

Barzilai N, Guo H, Mahoney EM, Caporossi S, Golm GT, Langdon RB, Williams-Herman D, Kaufman KD, Amatruda JM, Goldstein BJ, Steinberg H Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. *Curr Med Res Opin* 2011;27:1049-58 [21428727] 10.1185/03007995.2011.568059

Chan, 2008:

Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams-Herman D Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. *Diabetes Obes Metab* 2008;10:545-55 [18518892] 10.1111/j.1463-1326.2008.00914.x

Mohan , 2009:

Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, Amatruda JM, Stein PP, Kaufman KD Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. *Diabetes Res Clin Pract* 2009;83:106-16 [19097665] 10.1016/j.diabres.2008.10.009

Nonaka, 2008:

Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, Suzuki H, Hirayama Y, Ahmed T, Davies MJ, Stein PP Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. *Diabetes Res Clin Pract* 2008;79:291-8 [17933414] 10.1016/j.diabres.2007.08.021

Raz, 2006:

Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. *Diabetologia* 2006;49:2564-71 [17001471] 10.1007/s00125-006-0416-z

Vilsbll, 2010:

Vilsbll T, Rosenstock J, Yki-Jrvinen H, Cefalu WT, Chen Y, Luo E, Musser B, Andryuk PJ, Ling Y, Kaufman KD, Amatruda JM, Engel SS, Katz L Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. *Diabetes Obes Metab* 2010;12:167-77 [20092585] [10.1111/j.1463-1326.2009.01173.x](https://doi.org/10.1111/j.1463-1326.2009.01173.x)

Charbonnel, 2006:

Charbonnel B, Karasik A, Liu J, Wu M, Meininger G Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. *Diabetes Care* 2006;29:2638-43 [17130197] [10.2337/dc06-0706](https://doi.org/10.2337/dc06-0706)

Nauck, 2007:

Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes Obes Metab* 2007;9:194-205 [17300595] [10.1111/j.1463-1326.2006.00704.x](https://doi.org/10.1111/j.1463-1326.2006.00704.x)

Seck TL, Engel SS, Williams-Herman DE, Sisk CM, Golm GT, Wang H, Kaufman KD, Goldstein BJ Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. *Diabetes Res Clin Pract* 2011;93:e15-7 [21477878] [10.1016/j.diabres.2011.03.006](https://doi.org/10.1016/j.diabres.2011.03.006)

Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein PP, Kaufman KD, Amatruda JM Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. *Int J Clin Pract* 2010;64:562-76 [20456211] [10.1111/j.1742-1241.2010.02353.x](https://doi.org/10.1111/j.1742-1241.2010.02353.x)

raz, 2008:

Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, Langdon RB, Stein PP, Alba M Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. *Curr Med Res Opin* 2008;24:537-50 [18194595] [10.1185/030079908X260925](https://doi.org/10.1185/030079908X260925)

Scott (sit vs pbo on top met), 2007:**

Scott R, Loeys T, Davies MJ, Engel SS Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. *Diabetes Obes Metab* 2008;10:959-69 [18201203] [10.1111/j.1463-1326.2007.00839.x](https://doi.org/10.1111/j.1463-1326.2007.00839.x)

Rosenstock , 2006:

Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Clin Ther* 2006;28:1556-68 [17157112] [10.1016/j.clinthera.2006.10.007](https://doi.org/10.1016/j.clinthera.2006.10.007)

Rosenstock (sit on top pio vs pbo), 2006:

Ristic S, Byiers S, Foley J, Holmes D Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. *Diabetes Obes Metab* 2005;7:692-8 [16219012] [10.1111/j.1463-1326.2005.00539.x](https://doi.org/10.1111/j.1463-1326.2005.00539.x)

Hermansen, 2007:

Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. *Diabetes Obes Metab* 2007;9:733-45 [17593236] [10.1111/j.1463-1326.2007.00744.x](https://doi.org/10.1111/j.1463-1326.2007.00744.x)

Rigby , 2010:

Rigby SP, Handelsman Y, Lai YL, Abby SL, Tao B, Jones MR Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. *Endocr Pract* 2010;16:53-63 [19789153] [10.4158/EP09146.OR](https://doi.org/10.4158/EP09146.OR)

Al Sifri, 2011:

Al Sifri S, Basiounny A, Echtay A, Al Omari M, Harman-Boehm I, Kaddaha G, Al Tayeb K, Mahfouz AS, Al Elq A, Radican L, Ozesen C, Katzeff HL, Musser BJ, Suryawanshi S, Girman CJ, Davies MJ, Engel SS The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea

during Ramadan: a randomised trial. Int J Clin Pract 2011;65:1132-40 [21951832] [10.1111/j.1742-1241.2011.02797.x](https://doi.org/10.1111/j.1742-1241.2011.02797.x)

Iwamoto , 2010:

Iwamoto Y, Tajima N, Kadowaki T, Nonaka K, Taniguchi T, Nishii M, Arjona Ferreira JC, Amatruda JM Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010;12:613-22 [20590736] [10.1111/j.1463-1326.2010.01197.x](https://doi.org/10.1111/j.1463-1326.2010.01197.x)

Scott* (sit vs glipi), 2007:

Scott R, Wu M, Sanchez M, Stein P Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61:171-80 [17156104] [10.1111/j.1742-1241.2006.01246.x](https://doi.org/10.1111/j.1742-1241.2006.01246.x)

Goldstein (sit vs met), 2007:

Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87 [17485570] [10.2337/dc07-0627](https://doi.org/10.2337/dc07-0627)

Goldstein (sit+met vs met), 2007:

Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87 [17485570] [10.2337/dc07-0627](https://doi.org/10.2337/dc07-0627)

Prez-Monteverde, 2011:

Prez-Monteverde A, Seck T, Xu L, Lee MA, Sisk CM, Williams-Herman DE, Engel SS, Kaufman KD, Goldstein BJ Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naive patients with type 2 diabetes. Int J Clin Pract 2011;65:930-8 [21849007] [10.1111/j.1742-1241.2011.02749.x](https://doi.org/10.1111/j.1742-1241.2011.02749.x)

∞

Entry terms: sitagliptin, sitagliptin phosphate, Januvia, MK 0431, MK0431, MK-0431,